University of Birmingham researchers have been awarded £3.5 million funding from Johnson & Johnson to investigate mechanisms of response and non-response to biologic and targeted synthetic therapies in rheumatoid arthritis.
Editors at The Lancet Rheumatology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.A…
Historical redlining could be a structural determinant of inequities in present-day health-care utilisation patterns. Policy interventions that dismantle structural racism could reduce inequities in access…
Dr Mark Russell and Sherry Yang discuss the factors influencing initiation of biologics in underserved populations with rheumatoid arthritis in the UK, how historical redlining…
The initiation of biological and targeted synthetic DMARDs for patients with newly diagnosed rheumatoid arthritis varies markedly by ethnicity and age in the universal health-care…
Objective To evaluate the efficacy and safety of subcutaneous (SC) abatacept and standard of care (SOC) for the treatment of idiopathic inflammatory myopathy (IIM) over…
How dendritic cells (DCs) regulate human tissue immunity remains unclear. MacDonald, Elmesmari, Somma, Frew, et al. investigate the role of synovial tissue (ST) myeloid DCs in…
CDK7 inhibitors reverse inflammatory macrophage phenotypes and show therapeutic promise in rheumatoid arthritis models and patient synovial cells.
Objective Prior incidence estimates of psoriatic arthritis (PsA) vary considerably. We aimed to assess the annual incidence of clinically diagnosed PsA among adults in Sweden…
Objective Spondyloarthritis (SpA) is the most common extraintestinal manifestation of inflammatory bowel disease (IBD). The application of screening tools to detect SpA in patients with…
The Winter Rheumatology Symposium provides current, practical clinical information on the diagnosis & management of patients with rheumatic & immune disorders.
